Swadeshi Jagran Manch advocates for waiving animal trials in biosimilar approval process to make drugs more affordable and ...

Investing.com -- 4D Molecular Therapeutics (NASDAQ: FDMT) stock rose 36% after the company announced positive 60-week results from its 4D-150 SPECTRA clinical trial in diabetic macular edema (DME) and ...

The designation was based on the therapy’s novel mechanism and data showing its anti-tumour activity in B-cell malignancies.

The Phase I trial of ENERGI-F705PD tablet was a randomized, double-blind, placebo-controlled study designed to evaluate the ...

Retail chatter around Apellis Pharmaceuticals spiked Thursday after Goldman Sachs raised its price target to $26 from $24, citing strong quarterly performance and long-term growth potential through ...

I'm a tennis professional with over two decades of playing experience and 8 years of coaching under my belt. After graduating ...

D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level4D-150 demonstrated durable and dose-dependent clinical activity with sustained gains in ...

The target is to reduce its workforce to less than 5,000 from a level of 5,800 at the end of 2024, said chief executive ...